Skip to content
Screener

Immix Biopharma, Inc. IMMX Q2 2025 earnings

Reported August 8, 2025 · Before market open

EPS-$0.22Miss by $0.01
EPS estimate-$0.21

Next report

Nov 6, 2026 (in 2 months)
EPS estimate-$0.18

Financials

Q2 2025

Income statement

See full
Operating income-$6.7M-42.9%
Net income-$6.6M-50.8%
EPS (diluted)-$0.22-46.7%

Balance sheet

See full
Cash & equivalents$11.6M-51.5%
Total debt$1.0M-4.4%
Total equity$4.7M-80.5%
Total assets$15.6M-45.8%

Cash flow

See full
Operating cash flow-$5.3M-1.0%
CapEx$127.6K+31.5%
Free cash flow-$5.4M-1.6%

Valuation & ratios

Valuation

as of 06/30/25
See full
Market cap$62.45M+9.6%
Enterprise value$51.85M+52.0%

Returns & leverage

See full
Return on equity-162%+225pp
Debt / equity0.2×+0.2×
Current ratio1.2×-5.8×

FAQ

When did Immix Biopharma, Inc. report Q2 2025 earnings?
Immix Biopharma, Inc. (IMMX) reported Q2 2025 earnings on August 8, 2025 before market open.
What were Immix Biopharma, Inc.'s Q2 2025 revenue and EPS?
Immix Biopharma, Inc. reported eps of $-0.22 for Q2 2025.
Did Immix Biopharma, Inc. beat estimates in Q2 2025?
EPS missed the consensus estimate of $-0.21 by $0.01.
How did Immix Biopharma, Inc.'s Q2 2025 results compare year-over-year?
Compared to the same quarter a year prior, eps declined 46.7% from $-0.15.
Where can I find Immix Biopharma, Inc.'s Q2 2025 SEC filings?
You can read the 10-Q periodic report (0001641172-25-022829) directly on SEC EDGAR. The filing index links above go to sec.gov.